Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors

Cancer Immunology, Immunotherapy

Volumn 59, Issue 7, 2010, Pages 1073-1081

  Lee, Sujin ^a,d   Yagita, Hideo ^b   Sayers, Thomas J ^c   Celis, Esteban ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b JUNTENDO UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DR5; Balb neuT mice; Bortezomib; Breast tumors; CpG

Indexed keywords

BORTEZOMIB; CPG OLIGODEOXYNUCLEOTIDE; DEATH RECEPTOR 5 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE; PYRAZINE DERIVATIVE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; MALE; PATHOLOGY; RAT; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; OLIGODEOXYRIBONUCLEOTIDES; PYRAZINES; RATS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

EID: 77953071740     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0834-0     Document Type: Article

References (33)

1. D Assudani HI Cho N DeVito N Bradley E Celis 2008 In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells Cancer Res 68 9892 9899 10.1158/0008-5472.CAN-08- 3134 1:CAS:528:DC%2BD1cXhsVegtbnK 19047170
2. J Blade MT Cibeira L Rosinol 2005 Bortezomib: a valuable new antineoplastic strategy in multiple myeloma Acta Oncol 44 440 448 10.1080/02841860510030002 1:CAS:528:DC%2BD2MXpvVSgsb0%3D 16118077 (Pubitemid 41191776)
3. AD Brooks T Ramirez U Toh J Onksen PJ Elliott WJ Murphy TJ Sayers 2005 The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis Ann N Y Acad Sci 1059 160 167 10.1196/annals.1339.042 1:CAS:528:DC%2BD28XhvFGnt7c%3D 16382051 (Pubitemid 43211618)
4. AF Carpentier G Auf JY Delattre 2003 CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma Front Biosci 8 e115 e127 10.2741/934 1:CAS:528:DC%2BD3sXitFygtLs%3D 12456326
5. HI Cho G Niu N Bradley E Celis 2008 Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors Cancer Immunol Immunother 57 1695 1703 10.1007/s00262-008-0465-x 1:CAS:528:DC%2BD1cXhtVejsbvK 18253731
6. N Corazza D Kassahn S Jakob A Badmann T Brunner 2009 TRAIL-induced apoptosis: between tumor therapy and immunopathology Ann N Y Acad Sci 1171 50 58 10.1111/j.1749-6632.2009.04905.x 1:CAS:528:DC%2BD1MXht1Sntb3I 19723037
7. TG Cotter 2009 Apoptosis and cancer: the genesis of a research field Nat Rev Cancer 9 501 507 10.1038/nrc2663 1:CAS:528:DC%2BD1MXnsFynt74%3D 19550425
8. TG Cotter SV Lennon JG Glynn SJ Martin 1990 Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells Anticancer Res 10 1153 1159 1:STN:280:DyaK3M%2FltlSgtg%3D%3D 2241096
9. E Cretney K Takeda MJ Smyth 2007 Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway Int J Biochem Cell Biol 39 280 286 10.1016/j.biocel.2006.10.005 1:CAS:528:DC%2BD28Xht12ktLrL 17097329 (Pubitemid 44855666)
10. M Dicato M Boccadoro J Cavenagh JL Harousseau H Ludwig J San Miguel P Sonneveld 2006 Management of multiple myeloma with bortezomib: experts review the data and debate the issues Oncology 70 474 482 10.1159/000099284 1:CAS:528:DC%2BD2sXjsVKmsrg%3D 17283449 (Pubitemid 46333769)
11. Green DR, Bissonnette RP, Cotter TG (1994) Apoptosis and cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 37-52
12. WH Hallett E Ames M Motarjemi I Barao A Shanker DL Tamang TJ Sayers D Hudig WJ Murphy 2008 Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition J Immunol 180 163 170 1:CAS:528:DC%2BD2sXhsVGjtb3K 18097016
13. C Hao JH Song B Hsi J Lewis DK Song KC Petruk DL Tyrrell NM Kneteman 2004 TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice Cancer Res 64 8502 8506 10.1158/0008-5472.CAN-04-2599 1:CAS:528: DC%2BD2cXhtVCjs7%2FF 15574753 (Pubitemid 39552059)
14. L Jung L Holle WS Dalton 2004 Discovery, development, and clinical applications of bortezomib Oncology (Williston Park) 18 4 13
15. JH Kim N Majumder H Lin J Chen LD Falo Jr Z You 2005 Enhanced immunity by NeuEDhsp70 DNA vaccine is needed to combat an aggressive spontaneous metastatic breast cancer Mol Ther 11 941 949 10.1016/j.ymthe.2005.01.003 1:CAS:528:DC%2BD2MXks1ajsbc%3D 15922965 (Pubitemid 40724113)
16. AM Krieg 2002 CpG motifs in bacterial DNA and their immune effects Annu Rev Immunol 20 709 760 10.1146/annurev.immunol.20.100301.064842 1:CAS:528:DC%2BD38XjtlWgtbw%3D 11861616 (Pubitemid 34293438)
17. SL McKenna TG Cotter 1997 Functional aspects of apoptosis in hematopoiesis and consequences of failure Adv Cancer Res 71 121 164 10.1016/S0065-230X(08)60098-6 1:CAS:528:DyaK2sXjvVOkur0%3D 9111865
18. Y Meng AF Carpentier L Chen G Boisserie JM Simon JJ Mazeron JY Delattre 2005 Successful combination of local CpG-ODN and radiotherapy in malignant glioma Int J Cancer 116 992 997 10.1002/ijc.21131 1:CAS:528:DC%2BD2MXpsVegtbw%3D 15856470 (Pubitemid 41209208)
19. C Monneret JP Buisson H Magdelenat 2005 A new therapy with bortezomib, an oncologic medicinal product of the year 2004 Ann Pharm Fr 63 343 349 1:CAS:528:DC%2BD2MXht1GmtbnL 16385784
20. P Nava-Parada G Forni KL Knutson LR Pease E Celis 2007 Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors Cancer Res 67 1326 1334 10.1158/0008-5472.CAN-06-3290 1:CAS:528:DC%2BD2sXht1yntrY%3D 17283170
21. A Nencioni L Wille G Dal Bello D Boy G Cirmena S Wesselborg C Belka P Brossart F Patrone A Ballestrero 2005 Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells Clin Cancer Res 11 4259 4265 10.1158/1078-0432.CCR-04-2496 1:CAS:528:DC%2BD2MXks1Gksbw%3D 15930365 (Pubitemid 40791593)
22. T Newsom-Davis S Prieske H Walczak 2009 Is TRAIL the holy grail of cancer therapy? Apoptosis 14 607 623 10.1007/s10495-009-0321-2 1:CAS:528: DC%2BD1MXivFSns7Y%3D 19194800
23. PG Richardson 2004 A review of the proteasome inhibitor bortezomib in multiple myeloma Expert Opin Pharmacother 5 1321 1331 10.1517/14656566.5.6.1321 1:CAS:528:DC%2BD2cXkt1Ghtbc%3D 15163277 (Pubitemid 38898619)
24. A Shanker AD Brooks CA Tristan JW Wine PJ Elliott H Yagita K Takeda MJ Smyth WJ Murphy TJ Sayers 2008 Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody J Natl Cancer Inst 100 649 662 10.1093/jnci/djn113 1:CAS:528: DC%2BD1cXlslymtbk%3D 18445820
25. A Shanker T Sayers 2007 Sensitizing tumor cells to immune-mediated cytotoxicity Adv Exp Med Biol 601 163 171 17713003
26. K Takeda Y Kojima K Ikejima K Harada S Yamashina K Okumura T Aoyama S Frese H Ikeda NM Haynes E Cretney H Yagita N Sueyoshi N Sato Y Nakanuma MJ Smyth 2008 Death receptor 5-mediated apoptosis contributes to cholestatic liver disease Proc Natl Acad Sci USA 105 10895 10900 10.1073/pnas.0802702105 1:CAS:528:DC%2BD1cXpvFOisrg%3D 18667695
27. K Takeda N Yamaguchi H Akiba Y Kojima Y Hayakawa JE Tanner TJ Sayers N Seki K Okumura H Yagita MJ Smyth 2004 Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy J Exp Med 199 437 448 10.1084/jem.20031457 1:CAS:528:DC%2BD2cXhsFKhuro%3D 14769851 (Pubitemid 38233828)
28. T Uno K Takeda Y Kojima H Yoshizawa H Akiba RS Mittler F Gejyo K Okumura H Yagita MJ Smyth 2006 Eradication of established tumors in mice by a combination antibody-based therapy Nat Med 12 693 698 10.1038/nm1405 1:CAS:528:DC%2BD28XltlOjsb4%3D 16680149 (Pubitemid 43865240)
29. RL VanOosten TS Griffith 2007 Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy Cancer Res 67 11980 11990 10.1158/0008-5472.CAN-07-1526 1:CAS:528:DC%2BD2sXhsVCjs7bP 18089829
30. H Wagner 2002 Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity Curr Opin Microbiol 5 62 69 10.1016/S1369-5274(02) 00287-4 1:CAS:528:DC%2BD38XhtVKqsb8%3D 11834371 (Pubitemid 34118159)
31. H Xiang JA Fox K Totpal M Aikawa K Dupree D Sinicropi J Lowe E Escandon 2002 Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors Oncogene 21 3611 3619 10.1038/sj.onc.1205449 1:CAS:528: DC%2BD38XktlWju7o%3D 12032863 (Pubitemid 34587693)
32. S Yamamoto T Yamamoto Y Nojima K Umemori S Phalen DN McMurray E Kuramoto S Iho R Takauji Y Sato T Yamada N Ohara S Matsumoto Y Goto K Matsuo T Tokunaga 2002 Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development Jpn J Infect Dis 55 37 44 1:CAS:528:DC%2BD38XmtFWmsrY%3D 12082305
33. W Zou S Chen X Liu P Yue MB Sporn FR Khuri SY Sun 2007 c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells Cancer Biol Ther 6 1614 1620 1:CAS:528: DC%2BD1cXjslWlsLo%3D 18253090